Maze Therapeutics, Inc. (MAZE): A Bull Case Theory [Yahoo! Finance]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Yahoo! Finance
In this article, we will summarize the bulls' thesis on MAZE. Maze Therapeutics, Inc.'s share was trading at $23.25 as of September 15th. MAZE's forward P/E was 8.53 according to Yahoo Finance. Tempus AI (TEM) Initiated at ‘Buy' with $60 Price Target by BTIG Sergey Nivens/Shutterstock.com Maze Therapeutics (NASDAQ: MAZE) is showing a compelling move in the small-cap biotech space, driven by a rare combination of premium financing, positive clinical data, and breakout trading volume. The company recently secured a $150 million private placement at $16.25 per share, above the market price, signaling strong institutional conviction in its pipeline. Biotech investors rarely pay a premium unless the underlying data is promising. This confidence is reinforced by the progress of Maze's lead program, MZE782, which demonstrated robust Phase 1 safety and compelling pharmacodynamics in a rare kidney disease, positioning the therapy as a potential market differentiator. The funding extend
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
MAZE
Earnings
- 11/6/25 - Beat
MAZE
Sec Filings
- 12/4/25 - Form 144
- 11/21/25 - Form 4
- 11/21/25 - Form 144
- MAZE's page on the SEC website